Ranbaxy to provide generics in Germany under deal with AOK
This article was originally published in Scrip
Executive Summary
Basics, a 100% subsidiary of Ranbaxy Laboratories, is to provide medicines in Germany following an agreement with AOK Baden-Wurttemberg. The agreement, which runs for two years, comes into effect on June 1st and includes Ranbaxy's cefaclor Basics (exclusive for all 15 AOK regional associations and five zones) and tamsulosin Basics (exclusive for 13 AOK regional associations and four zones ,with the exception of AOK Rhineland/Hamburg and AOK Westfalen Lippe zone). AOK is Germany's biggest health insurance group and its subscribers comprise nearly 24 million people.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.